Publication

Effects of Sodium-Glucose Co-transporter 2 Inhibition with Empaglifozin on Renal Structure and Function in Non-diabetic Rats with Left Ventricular Dysfunction After Myocardial Infarction

Yurista, S., Sillje, H., van Goor, H., Hillebrands, J-L., Heerspink, H. J. L., de Menezes Montenegro, L., Oberdorf, S., Boer, de, R. & Westenbrink, D., Jun-2020, In : Cardiovascular Drugs and Therapy. 34, 3, p. 311-321 11 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

Yurista, S., Sillje, H., van Goor, H., Hillebrands, J-L., Heerspink, H. J. L., de Menezes Montenegro, L., Oberdorf, S., Boer, de, R., & Westenbrink, D. (2020). Effects of Sodium-Glucose Co-transporter 2 Inhibition with Empaglifozin on Renal Structure and Function in Non-diabetic Rats with Left Ventricular Dysfunction After Myocardial Infarction. Cardiovascular Drugs and Therapy, 34(3), 311-321. https://doi.org/10.1007/s10557-020-06954-6

Author

Yurista, Salva ; Sillje, Herman ; van Goor, Harry ; Hillebrands, Jan-Luuk ; Heerspink, Hiddo J.L. ; de Menezes Montenegro, Luiz ; Oberdorf, Silke ; Boer, de, Rudolf ; Westenbrink, Daan. / Effects of Sodium-Glucose Co-transporter 2 Inhibition with Empaglifozin on Renal Structure and Function in Non-diabetic Rats with Left Ventricular Dysfunction After Myocardial Infarction. In: Cardiovascular Drugs and Therapy. 2020 ; Vol. 34, No. 3. pp. 311-321.

Harvard

Yurista, S, Sillje, H, van Goor, H, Hillebrands, J-L, Heerspink, HJL, de Menezes Montenegro, L, Oberdorf, S, Boer, de, R & Westenbrink, D 2020, 'Effects of Sodium-Glucose Co-transporter 2 Inhibition with Empaglifozin on Renal Structure and Function in Non-diabetic Rats with Left Ventricular Dysfunction After Myocardial Infarction', Cardiovascular Drugs and Therapy, vol. 34, no. 3, pp. 311-321. https://doi.org/10.1007/s10557-020-06954-6

Standard

Effects of Sodium-Glucose Co-transporter 2 Inhibition with Empaglifozin on Renal Structure and Function in Non-diabetic Rats with Left Ventricular Dysfunction After Myocardial Infarction. / Yurista, Salva; Sillje, Herman; van Goor, Harry; Hillebrands, Jan-Luuk; Heerspink, Hiddo J.L. ; de Menezes Montenegro, Luiz; Oberdorf, Silke; Boer, de, Rudolf; Westenbrink, Daan.

In: Cardiovascular Drugs and Therapy, Vol. 34, No. 3, 06.2020, p. 311-321.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

Yurista S, Sillje H, van Goor H, Hillebrands J-L, Heerspink HJL, de Menezes Montenegro L et al. Effects of Sodium-Glucose Co-transporter 2 Inhibition with Empaglifozin on Renal Structure and Function in Non-diabetic Rats with Left Ventricular Dysfunction After Myocardial Infarction. Cardiovascular Drugs and Therapy. 2020 Jun;34(3):311-321. https://doi.org/10.1007/s10557-020-06954-6


BibTeX

@article{733c8ffec8774d08b761d6103b3925b0,
title = "Effects of Sodium-Glucose Co-transporter 2 Inhibition with Empaglifozin on Renal Structure and Function in Non-diabetic Rats with Left Ventricular Dysfunction After Myocardial Infarction",
abstract = "BACKGROUND: The use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) is currently expanding to cardiovascular risk reduction in non-diabetic subjects, but renal (side-)effects are less well studied in this setting.METHODS: Male non-diabetic Sprague Dawley rats underwent permanent coronary artery ligation to induce MI, or sham surgery. Rats received chow containing empagliflozin (EMPA) (30 mg/kg/day) or control chow. Renal function and electrolyte balance were measured in metabolic cages. Histological and molecular markers of kidney injury, parameters of phosphate homeostasis and bone resorption were also assessed.RESULTS: EMPA resulted in a twofold increase in diuresis, without evidence for plasma volume contraction or impediments in renal function in both sham and MI animals. EMPA increased plasma magnesium levels, while the levels of glucose and other major electrolytes were comparable among the groups. Urinary protein excretion was similar in all treatment groups and no histomorphological alterations were identified in the kidney. Accordingly, molecular markers for cellular injury, fibrosis, inflammation and oxidative stress in renal tissue were comparable between groups. EMPA resulted in a slight increase in circulating phosphate and PTH levels without activating FGF23-Klotho axis in the kidney and bone mineral resorption, measured with CTX-1, was not increased.CONCLUSIONS: EMPA exerts profound diuretic effects without compromising renal structure and function or causing significant electrolyte imbalance in a non-diabetic setting. The slight increase in circulating phosphate and PTH after EMPA treatment was not associated with evidence for increased bone mineral resorption suggesting that EMPA does not affect bone health.",
author = "Salva Yurista and Herman Sillje and {van Goor}, Harry and Jan-Luuk Hillebrands and Heerspink, {Hiddo J.L.} and {de Menezes Montenegro}, Luiz and Silke Oberdorf and {Boer, de}, Rudolf and Daan Westenbrink",
year = "2020",
month = jun,
doi = "10.1007/s10557-020-06954-6",
language = "English",
volume = "34",
pages = "311--321",
journal = "Cardiovascular Drugs and Therapy",
issn = "0920-3206",
publisher = "SPRINGER",
number = "3",

}

RIS

TY - JOUR

T1 - Effects of Sodium-Glucose Co-transporter 2 Inhibition with Empaglifozin on Renal Structure and Function in Non-diabetic Rats with Left Ventricular Dysfunction After Myocardial Infarction

AU - Yurista, Salva

AU - Sillje, Herman

AU - van Goor, Harry

AU - Hillebrands, Jan-Luuk

AU - Heerspink, Hiddo J.L.

AU - de Menezes Montenegro, Luiz

AU - Oberdorf, Silke

AU - Boer, de, Rudolf

AU - Westenbrink, Daan

PY - 2020/6

Y1 - 2020/6

N2 - BACKGROUND: The use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) is currently expanding to cardiovascular risk reduction in non-diabetic subjects, but renal (side-)effects are less well studied in this setting.METHODS: Male non-diabetic Sprague Dawley rats underwent permanent coronary artery ligation to induce MI, or sham surgery. Rats received chow containing empagliflozin (EMPA) (30 mg/kg/day) or control chow. Renal function and electrolyte balance were measured in metabolic cages. Histological and molecular markers of kidney injury, parameters of phosphate homeostasis and bone resorption were also assessed.RESULTS: EMPA resulted in a twofold increase in diuresis, without evidence for plasma volume contraction or impediments in renal function in both sham and MI animals. EMPA increased plasma magnesium levels, while the levels of glucose and other major electrolytes were comparable among the groups. Urinary protein excretion was similar in all treatment groups and no histomorphological alterations were identified in the kidney. Accordingly, molecular markers for cellular injury, fibrosis, inflammation and oxidative stress in renal tissue were comparable between groups. EMPA resulted in a slight increase in circulating phosphate and PTH levels without activating FGF23-Klotho axis in the kidney and bone mineral resorption, measured with CTX-1, was not increased.CONCLUSIONS: EMPA exerts profound diuretic effects without compromising renal structure and function or causing significant electrolyte imbalance in a non-diabetic setting. The slight increase in circulating phosphate and PTH after EMPA treatment was not associated with evidence for increased bone mineral resorption suggesting that EMPA does not affect bone health.

AB - BACKGROUND: The use of sodium-glucose co-transporter 2 inhibitors (SGLT2i) is currently expanding to cardiovascular risk reduction in non-diabetic subjects, but renal (side-)effects are less well studied in this setting.METHODS: Male non-diabetic Sprague Dawley rats underwent permanent coronary artery ligation to induce MI, or sham surgery. Rats received chow containing empagliflozin (EMPA) (30 mg/kg/day) or control chow. Renal function and electrolyte balance were measured in metabolic cages. Histological and molecular markers of kidney injury, parameters of phosphate homeostasis and bone resorption were also assessed.RESULTS: EMPA resulted in a twofold increase in diuresis, without evidence for plasma volume contraction or impediments in renal function in both sham and MI animals. EMPA increased plasma magnesium levels, while the levels of glucose and other major electrolytes were comparable among the groups. Urinary protein excretion was similar in all treatment groups and no histomorphological alterations were identified in the kidney. Accordingly, molecular markers for cellular injury, fibrosis, inflammation and oxidative stress in renal tissue were comparable between groups. EMPA resulted in a slight increase in circulating phosphate and PTH levels without activating FGF23-Klotho axis in the kidney and bone mineral resorption, measured with CTX-1, was not increased.CONCLUSIONS: EMPA exerts profound diuretic effects without compromising renal structure and function or causing significant electrolyte imbalance in a non-diabetic setting. The slight increase in circulating phosphate and PTH after EMPA treatment was not associated with evidence for increased bone mineral resorption suggesting that EMPA does not affect bone health.

U2 - 10.1007/s10557-020-06954-6

DO - 10.1007/s10557-020-06954-6

M3 - Article

C2 - 32185580

VL - 34

SP - 311

EP - 321

JO - Cardiovascular Drugs and Therapy

JF - Cardiovascular Drugs and Therapy

SN - 0920-3206

IS - 3

ER -

ID: 120354098